Urolog. pro Praxi, 2005; 1: 6-9

TESTICULAR CANCER

prof. MUDr. Dalibor Ondruš DrSc1, RNDr. PhDr. Martina Cuninková2
1 Onkologická klinika LF UK, Onkologický ústav sv. Alžbety, Bratislava
2 Oddelenie epidemiológie nádorov, Ústav experimentálnej onkológie SAV, Bratislava

Testicular cancer is the most freqent malignancy among 20–40 years old males. There has been significant increase of its incidence during last 40 years, with reference to individual countries. Despite these facts the management of testicular cancer is on the highest level from all the urological malignancies. There have been new challenges in diagnosis, treatment and prevention of therapeutic toxicity. The most important way of therapeutic modalities is the multidisciplinary approach (surgery and the cisplatin-based chemotherapy). The research on drug-toxicity elimination has been still proceeding.

Keywords: Key words: testicular tumors, orchiectomy, multidisciplinary approach, self-examination.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ondruš D, Cuninková M. TESTICULAR CANCER. Urol. praxi. 2005;6(1):6-9.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrahámová J. Nádory varlat. Postgraduální medicína, 2003; 5(6): 2-18.
    2. Horňák M, Maťoška J. Nádory testis, diagnostika a liečba. Bratislava, Veda 1990: 260.
    3. Laguna P, Pizzocaro G, Klepp O, Algaba F, Kisbenedek L, Leiva O. Guidelines on Testicular Cancer, Arnhem, EAU Central Office 2001. Go to original source...
    4. Molnárová A. Úloha rádioterapie v liečbe seminómov. Klin. Onkol., 9, 1999; suppl. 9.
    5. Mostofi FK, Sobin LH. Histological typing of testis tumours. International histological classification of tumours. No. 16, Geneva, WHO 1977.
    6. Ondruš D. Dlhodobé skúsenosti s diferencovaným liečebným prístupom u pacientov s neseminomatóznym nádorom testis v I. klinickom štádiu. Urológia, 2003; 9(3): s. 20-25.
    7. Peckham MJ, Barrett A, Husband JE, Hendry WF. Orchiectomy alone in testicular stage I nonseminomatous germ-cell tumours. Lancet, 1982; 2(8300): 678-680. Go to original source... Go to PubMed...
    8. Peckham MJ, McElwain TJ, Barrett A, Hendry WF. Combined management of malignant teratoma of the testis. Lancet, 1979; 2(8137): 267-270. Go to original source... Go to PubMed...
    9. Pleško I, Cuninková M. Výskyt a vývoj zhubných nádorov uropoetického systému a mužských pohlavných orgánov na Slovensku. Urológia, 2003; 9(1): 41-47.
    10. Pleško I, Obšitniková A, Štefaňáková D, et al. Incidencia zhubných nádorov v Slovenskej republike 2000. Bratislava, Národný onkologický register SR 2003: 207 s.
    11. Sobin LH, Wittekind Ch. TNM classification of malignant tumors. 6th ed., New York, Willey-Liss 2002. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.